Tilray expands its footprint on medical cannabis in Europe


NEW YORK–(COMMERCIAL THREAD) – Tilray, Inc. (“Tilray”) (NASDAQ | TSX: TLRY), a global pioneer in the research, cultivation, production and distribution of medical cannabis, today announced that it has been selected by the Luxembourg Ministry of Health as supplier of certified Good Manufacturing Practices (GMP) medical cannabis produced for the country’s medical cannabis program.

As a result of this selection, Tilray will supply a variety of its pharmaceutical grade medical cannabis products including extracts and dried flowers with varying degrees of THC and CBD for patients with various health conditions. These prescription medical cannabis products will be administered to eligible patients in Luxembourg under the supervision of physicians.

Irwin D. Simon, Chief Executive Officer, said: “We believe Tilray’s growth potential in the European Union represents a $ 1 billion opportunity, and today’s announcement affirms that we are transforming the potential in performance. With today’s validation from the Luxembourg Ministry of Health, Tilray now offers branded medical cannabis in 20 countries around the world – a testament to our high standards and our status as a trusted partner for patients in the world. need. We are proud to build this unparalleled global platform and will continue to advocate for patient access in Europe and countries around the world.

Denise Faltischek, Global Head and Chief Strategy Officer, added: “Tilray’s mission includes the unwavering belief that patients around the world must have access to safe, high-quality cannabinoid medicines. We are proud to expand this effort in Luxembourg and provide patients in need with pharmaceutical grade medical cannabis products. We are committed to being a trusted partner and will continue to leverage our strong medical platform to increase access to the highest quality medical cannabis for patients around the world.

Tilray operates two state-of-the-art, GMP-certified cannabis cultivation facilities in Europe, located in Cantanhede, Portugal, and Neumunster, Germany. The EU campus in Portugal is a multi-faceted production facility that includes the cultivation, extraction, processing and packaging of medical cannabis. It also serves as a hub to support Tilray’s clinical research and product development efforts across Europe. In addition, Tilray has established sales and distribution agreements to supply medical cannabis through major pharmaceutical distribution channels, including CC Pharma, throughout Germany and the EU, which will provide patients with access to the Tilray GMP certified finished medical cannabis.

About Tilray

Tilray, Inc. (Nasdaq: TLRY; TSX: TLRY) is a leading global cannabis lifestyle and consumer packaged product companies with operations in Canada, the United States, Europe, Australia and in Latin America that changes people’s lives for the better – one person at a time – by inspiring and enabling the global community to live the best of their lives by providing them with products that meet the needs of their mind, their body and soul and invoke a feeling of well-being. Tilray’s mission is to be the trusted partner of its patients and consumers by offering them a cultivated experience, health and well-being through differentiated high-quality brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and alcoholic drinks.

For more information on Tilray and Tilray Europe, visit www.Tilray.eu.com

Forward-looking statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (collectively, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act. of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements may be identified by words such as “foresee”, “future”, “should”, “could”, “enable”, “potential”, “contemplate”, “believe”, “anticipate”, “estimate,” “” Plan “,” expect “,” intend “,” may “,” plan “,” “” “” “and the negative of these terms or similar expressions, although all forward-looking statements do not contain these identifying words. Certain significant factors, estimates, objectives, projections or assumptions have been used in drawing conclusions contained in forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievements to differ materially from any forward-looking statement, and other risks and uncertainties currently unknown to the Company or which the Company deems immaterial could also cause actual results or events differ materially from those expressed in the forward-looking statements contained in this document. For a more detailed discussion of these risks and other factors, see Tilray’s last filed annual information form and Tilray’s annual report on Form 10-K (and other periodic reports filed with the SEC) of Tilray filed with the authorities. applicable securities regulations and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company assumes no obligation to publicly update these forward-looking statements to reflect new information, subsequent events or otherwise, except as required by laws on applicable securities.


About Author

Leave A Reply